Gilead and EVOQ Therapeutics announce collaboration to advance immunotherapies Therapeutics Gilead receives the rights to exclusively license EVOQ’s NanoDisc Technology to develop and commercialize immunotherapy products for rheumatoid arthritis and lupus. Read more January 3, 2023/by Business Wire https://www.pharmalive.com/wp-content/uploads/2020/09/Gilead-Logo-GCP_Primarylarge_1.jpg 160 480 Business Wire https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Business Wire2023-01-03 08:30:032023-01-03 08:59:17Gilead and EVOQ Therapeutics announce collaboration to advance immunotherapies
